Intracellular Zinc-Dependent TAS2R8 Gene Expression Through CTCF Activa- Tion

Total Page:16

File Type:pdf, Size:1020Kb

Intracellular Zinc-Dependent TAS2R8 Gene Expression Through CTCF Activa- Tion Biomedical Research (Tokyo) 41 (5) 217–225, 2020 Intracellular zinc-dependent TAS2R8 gene expression through CTCF activa- tion 1 1, 2 2 1, 3 2, 4 Tsuyoshi KOJIMA , Toyonobu MAEDA , Atsuko SUZUKI , Tetsuo YAMAMORI , and Yasumasa KATO Departments of 1 Oral Rehabilitation and 4 Oral Physiology and Biochemistry, Ohu University Graduate School of Dentistry, Koriyama 963-8611, Japan; Departments of 2 Oral Function and Molecular Biology and 3 Prosthetic Dentistry, Ohu University School of Dentistry, Koriyama 963-8611, Japan (Received 21 April 2020; and accepted 7 June 2020) ABSTRACT Taste-2 receptors (TAS2Rs), which belong to the G-protein coupled receptor (GPCR) family, are receptors for bitter taste perception. The aim of this study was to investigate whether zinc defi- ciency affects the expression of TAS2R genes. The promoter activity of the TAS2R7, TAS2R8, and TAS2R42 genes were determined in Ca9-22 oral squamous cell carcinoma cells cultured in the presence or absence of zinc. Luciferase reporter assays showed that zinc deprivation inhibited TAS2R8 promoter activity, but not the promoter activity of the other two genes. Treatment of the cells with N,N,N’,N’-tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN), an intracellular chela- tor of Zn2+, in the presence of 10% fetal bovine serum reduced TAS2R8 promoter activity. Trunca- tion/deletion mutants of TAS2R8 promoter-luciferase constructs showed that the region from nucleotide −1152 to nucleotide −925 was critical for intracellular zinc dependency and contained a CCCTC-binding factor (CTCF) binding motif. A chromatin immunoprecipitation (ChiP) assay showed that CTCF bound specifically to this region, a binding abrogated by zinc deficiency, sug- gesting that CTCF plays a critical role in zinc-dependent bitter taste perception through TAS2R8. TAS2R, which belong to the G-protein coupled re- INTRODUCTION ceptor (GPCR) family. TAS1R and TAS2R each has Basic taste signals are categorized into five groups, isotypes, with various monomers and heterodimers salt, sour, sweet, bitter, and umami, with these sen- functioning as different types of taste receptors. For sory systems evolving to allow nutrition and avoid example, the heterodimers TAS1R1/TAS1R3 and potentially noxious and/or poisonous chemicals TAS1R2/TAS1R3 act as taste receptors for umami (Chandrashekar et al. 2006). In humans, taste is an and sweet, respectively (Li et al. 2002; Nelson et al. important sensory system for enjoyment of food and 2002), and all TAS2R monomers, comprised of ≈30 drink. Taste perceptions are associated with different subtypes, are utilized for bitter taste perception receptor molecules, including sodium channels for (Martin and Dupré 2016). A comparison of TAS2R8 salt, polycystic kidney disease 2-like 1 (PKD2L1) and TAS2R39 showed that they differ in recogniz- for sour, and taste receptors (TASRs) for sweet, bit- ing specific bitter tastes, with each TAS2R subtype ter and umami (Martin and Dupré 2016). TASRs having high ligand specificity (Ueno et al. 2011). can be categorized into two groups, TAS1R and Because zinc is an important co-factor for matrix metalloproteinases (MMPs) and zinc finger proteins, Address correspondence to: Yasumasa Kato, Department its deprivation for long periods of time reduces the of Oral Function and Molecular Biology, Ohu Universi- ty School of Dentistry, Koriyama 963-8611, Japan The work is part of the Ph.D. thesis of Tsuyoshi Tel: +81-24-932-8978 Kojima at Ohu University Graduate School of Dentist- E-mail: [email protected] ry, Koriyama, Japan. 218 T. Kojima et al. activity of these proteins. Zinc finger is a protein dual-luciferase® reporter assay system was from motif that stabilizes protein folding by coordination Promega (Madison, WI, USA). The intracellular with one or more Zn2+ ions. The nuclear protein membrane-permeable ion chelator N,N,N’,N’- CCCTC-binding factor (CTCF), an 11-zinc finger tetrakis(2-pyridinylmethyl)-1,2-ethanediamine (TPEN) protein, functions as an insulator (Ong and Corces and the insoluble formazan form of 3-(4,5-dimeth- 2014). Insulators mediate intra- and inter-chromo- ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide somal interactions and play a role in allowing or (MTT) were from Dojindo (Kumamoto, Japan). preventing three-dimensional folding between en- Xfect transfection reagent, PrimeSTAR GXL and hancers and promoters in distal regions, thereby in- In-Fusion® HD Cloning Kit were from Takara (To- ducing or repressing gene transcription. CTCF null kyo, Japan). mice are embryonically lethal (Moore et al. 2012), suggesting that CTCF-target molecules have played Antibodies. Anti-CTCF rabbit monoclonal antibody important roles in morphogenesis during evolution. (mAb) was purchased from abcam (Cambridge, UK) CTCF promotes alternative splicing by RNA poly- and mouse IgG1 (isotype control) was from MBL merase II through a process of exon inclusion (Nagoya, Japan). (Shukla et al. 2011) and also contributes to genomic imprinting (Fedoriw et al. 2004). In breast cancer, a Cells and cell culture. HEK293 cells, which were CTCF binding motif was found in the 3’ flanking derived from human embryonic kidney, were pur- region of the MMP7 gene, and a single nucleotide chased from the Japanese Collection of Research polymorphism (SNP) in this motif was shown to be Bioresources (JCRB) Cell Bank (Osaka, Japan), and associated with reduced breast cancer susceptibility human gingival squamous carcinoma (Ca9-22) cells and MMP7 promoter activity (Beeghly-Fadiel et al. were the kind gift of Dr. Kimiharu Hirose (Ohu 2008). CTCF bound to several molecules, including University School of Dentistry, Koriyama, Japan). transcription factor II-I (TFII-I) (Peña-Hermández et Both cell lines were grown in DMEM (high glu- al. 2015), the TATA-binding protein associated fac- cose) supplemented with 10% fetal bovine serum tor 3 (TAF3) (Liu et al. 2011), coheshin (Phillips- (FBS) and subcultured by treatment with 0.25% Cremins et al. 2013), and Smad2 (Van Bortle et al. trypsin/0.02% EDTA. After reaching confluency, the 2015), was shown to function as a transcriptional cells were washed twice with Mg2+ and Ca2+-free activator. Thus, CTCF functions as an architectural phosphate buffered saline (PBS(–)) and maintained protein in response to intracellular signal transduc- in serum-free DMEM (zinc-deprived medium) or in tion. serum-free DMEM supplemented with 15.3 μM Although zinc deprivation disrupts taste percep- ZnSO4 to yield a final concentration of 100 μg/dL, tion, the association of zinc deprivation with TAS2R the serum concentration of zinc in healthy males expression has not been determined. Although tran- (zinc-adequate medium) (Buxaderas and Farre-Rovira scription factors involving TAS2R gene regulation 1985), whose dose was confirmed to be within pre- by in silico analysis using cardiac gene expression vious reports (Deters et al. 2003; Sharif et al. 2012; data, were investigated, regulation of promoter ac- Takeda et al. 2018). To chelate intracellular zinc, tivity of the bitter taste TAS2R7, TAS2R8, TAS2R42 TPEN, a cell-permeable Zn2+ chelator (Treves et al. genes is not analyzed in-depth due to its low ex- 1994; Kolenko et al. 2001), was added to a final pression level in the heart (Foster et al. 2015). Be- concentration of 20 μM; as a vehicle control, etha- cause they are major molecules expressed in the nol was added to a final concentration <0.1%. taste buds (Hevezi et al. 2009), we focused to ex- amine their involvement in bitter taste disorder asso- Cloning, vector construction, transfection. Genome ciated with zinc deficiency. This study reports that DNA was extracted from CA9-22 cells using a Wiz- TAS2R8 expression is upregulated by CTCF finger eard genomic DNA purification kit (Promega). The protein. DNA sequences of TAS promoter regions were am- plified by polymerase chain reaction (PCR) using PrimeSTAR GXL with the primer sets shown in Ta- MATERIALS AND METHODS ble 1 and cloned into pGL4.20 vector (Promega) us- Reagents. Dulbecco’s Eagle Medium (DMEM) was ing an In-Fusion® HD Cloning Kit with the primer purchased from Sigma-Aldrich (Merck KGaA, sets shown in Table 2. Mutant expression vector was Darmstadt, Germany); fetal bovine serum (FBS) was constructed similarly using the primer sets in Ta- from Hyclone (South Logan, UT, USA); and the ble 3. TAS2R8 expression via CTCF 219 Table 1 PCR primer sets for amplifying gene promoter region Genes Sequences F: 5’- TAG CAA ACT ACT GAA TAC ATC TTT TCT ATC -3’ TAS2R7 R: 5’- TTC TTA GAT TTT GAT GTA GTT TTC TTT ACC -3’ F: 5’- CAT TTT CTC TTA TAT GCT ATT GGA AGT CAT -3’ TAS2R8 R: 5’- GTT TGT AGA GAG AAC AAT CTG ATT TCA AAT -3’ F: 5’- CTC CAG AGA CAA AAA AAT CCA AGT TTT TAA -3’ TAS2R42 R: 5’- CTC CAG AGA CAA AAA AAT CCA AGT TTT TAA -3’ F, forward; R, reverse. Table 2 In-Fusion primer sets for cloning the amplified promoter region of TAS2R8 into pGL4.20 vector Genes Sequences (Region, size) TAS2R7 F: 5’- ATC AAA ATC TAA GAA ATG GAA GAT GCC AAA -3’ (−3285 – +1, 3.3 kb) R: 5’- TTC AGT AGT TTG CTA AGG CCA GAG AAA TGT-3’ TAS2R8 F: 5’- GTT CTC TCT ACA AAC ATG GAA GAT GCC AAA -3’ (−2080 – +1, 2.1 kb) R: 5’- ATA TAA GAG AAA ATG AGG TAC CGG CCA GTT -3’ TAS2R8 F: 5’- CCT TGA CAG AGA GAG GAG GCA CAG TTA TGT -3’ (−1572 – +1, 1.6 kb) R: 5’- CTC TCT CTG TCA AGG TAC CGG CCA GTT A -3’ TAS2R42 F: 5’- TTT TTG TCT CTG GAG ATG GAA GAT GCC AAA -3’ (−4873 – +1, 4.9 kb) R: 5’- TTC CAA TAA GAC ATT TCC TCG AGG CTA GCG -3’ F, forward; R, reverse. Table 3 In-Fusion primer sets for cloning the deletion mutant of TAS2R8 pro- moter
Recommended publications
  • Genetic Association with Overall Survival of Taxane-Treated Lung
    Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Niu, Nifang et al. “Genetic Association with Overall Survival of Taxane-treated Lung Cancer Patients - a Genome-wide Association Study in Human Lymphoblastoid Cell Lines Followed by a Clinical Association Study.” BMC Cancer 12.1 (2012): 422. CrossRef. Web. As Published http://dx.doi.org/10.1186/1471-2407-12-422 Publisher BioMed Central Ltd. Version Final published version Citable link http://hdl.handle.net/1721.1/77191 Terms of Use Creative Commons Attribution Detailed Terms http://creativecommons.org/licenses/by/2.0 Genetic variations and paclitaxel response Supplementary Figure 1. Imputation analysis for 8 SNPs associated with both paclitaxel IC50 in LCLs and overall survival in lung cancer patients. SNPs within 200kb up-/downstream of those 8 SNPs were imputed. Black circles indicate SNPs observed by genotyping, while red triangles indicate imputed SNPs. The y-axis represents –log10(p-value) for the association of each SNP with paclitaxel IC50, and the x-axis represents the chromosomal locations of the SNPs. Genetic variations in paclitaxel response 1 Supplementary Table 1. Top 1415 SNPs that were associated with paclitaxel IC50 with p-values <10-3 and top 147 SNPs that were significantly associated with paclitaxel IC50
    [Show full text]
  • Ep 2329271 B1
    (19) & (11) EP 2 329 271 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 33/566 (2006.01) G01N 33/50 (2006.01) 20.06.2012 Bulletin 2012/25 (86) International application number: (21) Application number: 09775777.7 PCT/CH2009/000290 (22) Date of filing: 27.08.2009 (87) International publication number: WO 2010/022529 (04.03.2010 Gazette 2010/09) (54) METHODS TO IDENTIFY MODULATORS VERFAHREN ZUR IDENTIFIZIERUNG VON MODULATOREN PROCÉDÉS D’IDENTIFICATION DE MODULATEURS (84) Designated Contracting States: • EVANS PENNIMPEDE, Jenny Ellen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Cincinnati, OH 45241 (US) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR (74) Representative: Simmons, John Murray Givaudan Schweiz AG (30) Priority: 29.08.2008 US 92839 P Global Patents Überlandstrasse 138 (43) Date of publication of application: 8600 Dübendorf (CH) 08.06.2011 Bulletin 2011/23 (56) References cited: (73) Proprietor: Givaudan SA WO-A2-2006/053771 WO-A2-2006/086150 1214 Vernier (CH) WO-A2-2007/011859 US-A1- 2004 214 239 US-A1- 2008 038 739 (72) Inventors: • SLACK, Jay, Patrick Loveland, OH 45140 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar Et Al
    USOO9347934B2 (12) United States Patent (10) Patent No.: US 9,347,934 B2 Shekdar et al. (45) Date of Patent: May 24, 2016 (54) ASSAYS FOR IDENTIFYING COMPOUNDS 2008, OO38739 A1 2/2008 Li et al. THAT MODULATE BITTERTASTE 2008/0167286 A1* 7/2008 Gopalakrishnan et al. ........................ 514,21016 (71) Applicants: CHROMOCELL CORPORATION, 2010/01298.33 A1* 5/2010 Brune et al. ................. 435/721 North Brunswick, NJ (US); KRAFT FOODS GROUP BRANDS LLC, FOREIGN PATENT DOCUMENTS Northfield, IL (US) CN 1341632 A 3, 2002 CN 101583717 A 11, 2009 (72) Inventors: Kambiz Shekdar, New York, NY (US); CN 101828.111 A 9, 2010 Purvi Manoj Shah, Bridgewater, NJ WO WO-0038536 A2 7, 2000 WO WO-2004O29087 4/2004 (US); Joseph Gunnet, Flemington, NJ WO WO-2006053771 A2 5, 2006 (US); Jane V. Leland, Wilmette, IL WO WO-2007002026 A2 1/2007 (US); Peter H. Brown, Glenview, IL WO WO-2008057470 5, 2008 (US); Louise Slade, Morris Plains, NJ WO WO-2008119.195 A1 10, 2008 (US) WO WO-20081191.96 10, 2008 WO WO-20081191.97 10, 2008 (73) Assignees: Chromocell Corporation, North W WSi. A2 1929 Brunswick, NJ (US); Kraft Foods WO WO-2010O886.33 8, 2010 Group Brands LLC, Northfield, IL WO WO-2010O99983 A1 9, 2010 (US) WO WO-2013022947 2, 2013 (*) Notice: Subject to any disclaimer, the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. Bachmanov et al., Taste Receptor Genes, 2007, 27:389-414.* Behrens et al., Structural Requirements for Bitter Taste Receptor (21) Appl.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • G Protein‐Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
    [Show full text]
  • Origins and Adaptation in Humans: a Case Study of Taste and Lifestyle
    Origins and adaptation in humans : a case study of taste and lifestyle Agnès Sjöstrand To cite this version: Agnès Sjöstrand. Origins and adaptation in humans : a case study of taste and lifestyle. Human genetics. Université Pierre et Marie Curie - Paris VI; Uppsala universitet, 2015. English. NNT : 2015PA066724. tel-01609900 HAL Id: tel-01609900 https://tel.archives-ouvertes.fr/tel-01609900 Submitted on 4 Oct 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Université Pierre et Marie Curie Université d’Uppsala ED227 : Sciences de la Nature et de l’Homme : Écologie et Évolution UMR7206 Eco-Anthropologie et Ethnobiologie, Evolutionary Biology Center (Uppsala University) UMR5525 Laboratoire TIMC-IMAG. Origins and Adaptation in Humans a Case Study of Taste and Lifestyle Par Agnès Sjöstrand Thèse de doctorat de Génétique des populations Dirigée par Pr. Evelyne Heyer, Pr. Mattias Jakobsson & Dr. Michael Blum Présentée et soutenue publiquement le 20 novembre 2015 Devant un jury composé de : David Comas, professeur (rapporteur) Luis Quintana-Murci, directeur de recherche (rapporteur) Thierry Wirth, professeur (examinateur) Denis Pierron, chargé de recherche (examinateur) Åsa Johansson, chercheuse (examinatrice) Evelyne Heyer, professeure (directrice de thèse) Mattias Jakobsson, professeur (directeur de thèse) Michaël Blum, directeur de recherche (co-directeur de thèse) Ubuntu (Nguni word) Shosholoza (Ndebele word) List of Papers This thesis is based on the following papers, which are referred to in the text by their Roman numerals.
    [Show full text]
  • Genetic Variations in TAS2R3 and TAS2R4 Bitterness Receptors Modify
    www.nature.com/scientificreports OPEN Genetic variations in TAS2R3 and TAS2R4 bitterness receptors modify papillary carcinoma risk and Received: 10 January 2018 Accepted: 25 September 2018 thyroid function in Korean females Published: xx xx xxxx Jeong-Hwa Choi 1,2, Jeonghee Lee 1, Sarah Yang1,3, Eun Kyung Lee4, Yul Hwangbo4 & Jeongseon Kim 1 Type 2 taste receptors (T2Rs, TAS2Rs) mediate bitterness perception and are involved in diverse defence mechanisms in extraoral tissues. The thyrocyte-expressed T2Rs control thyroid hormone production, and this regulatory role may be associated with susceptibility to thyroid diseases. This study examined whether the variations in TAS2Rs modify the risk of papillary thyroid carcinoma (PTC) and whether such T2R-related PTC risk is associated with genetically modifed thyroid function. We conducted a case-control study with 763 Korean females, including 250 PTC cases. Seventy-three single-nucleotide polymorphisms in 13 TAS2R genes and the pre-diagnosis levels of 4 thyroid-related functional markers [total triiodothyronine (TT3), free thyroxine, thyroid-stimulating hormone and thyroglobulin] were analysed. Individuals with TAS2R3/4 CC haplotype (rs2270009 and rs2234001) were at a lower risk for PTC than those with the remaining haplotypes (odds ratio = 0.59, 95% confdence interval: 0.36–0.97). Furthermore, TT3 levels were signifcantly reduced for TAS2R3/4 CC haplotype carriers compared with other haplotype carriers (p = 0.005). No other genetic variants exhibited critical associations with the PTC phenotype and biomarkers. In summary, genetic variations in T2R3/4 bitterness receptors may modify the PTC risk, and the genetically modifed thyroid hormone level by those variations may be linked with the PTC-T2Rs association.
    [Show full text]
  • The Bitter Taste Receptor Tas2r14 Is Expressed in Ovarian Cancer and Mediates Apoptotic Signalling
    THE BITTER TASTE RECEPTOR TAS2R14 IS EXPRESSED IN OVARIAN CANCER AND MEDIATES APOPTOTIC SIGNALLING by Louis T. P. Martin Submitted in partial fulfilment of the requirements for the degree of Master of Science at Dalhousie University Halifax, Nova Scotia June 2017 © Copyright by Louis T. P. Martin, 2017 DEDICATION PAGE To my grandparents, Christina, Frank, Brenda and Bernie, and my parents, Angela and Tom – for teaching me the value of hard work. ii TABLE OF CONTENTS LIST OF TABLES ............................................................................................................. vi LIST OF FIGURES .......................................................................................................... vii ABSTRACT ....................................................................................................................... ix LIST OF ABBREVIATIONS AND SYMBOLS USED .................................................... x ACKNOWLEDGEMENTS .............................................................................................. xii CHAPTER 1 INTRODUCTION ........................................................................................ 1 1.1 G-PROTEIN COUPLED RECEPTORS ................................................................ 1 1.2 GPCR CLASSES .................................................................................................... 4 1.3 GPCR SIGNALING THROUGH G PROTEINS ................................................... 6 1.4 BITTER TASTE RECEPTORS (TAS2RS) ...........................................................
    [Show full text]
  • G Protein-Coupled Receptors
    Alexander, S. P. H., Christopoulos, A., Davenport, A. P., Kelly, E., Marrion, N. V., Peters, J. A., Faccenda, E., Harding, S. D., Pawson, A. J., Sharman, J. L., Southan, C., Davies, J. A. (2017). THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology, 174, S17-S129. https://doi.org/10.1111/bph.13878 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1111/bph.13878 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Wiley at https://doi.org/10.1111/bph.13878 . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2017/18: G protein-coupled receptors. British Journal of Pharmacology (2017) 174, S17–S129 THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors Stephen PH Alexander1, Arthur Christopoulos2, Anthony P Davenport3, Eamonn Kelly4, Neil V Marrion4, John A Peters5, Elena Faccenda6, Simon D Harding6,AdamJPawson6, Joanna L Sharman6, Christopher Southan6, Jamie A Davies6 and CGTP Collaborators 1 School of Life Sciences,
    [Show full text]
  • Inhibition of Bitter Taste from Oral Tenofovir Alafenamide S
    Supplemental material to this article can be found at: http://molpharm.aspetjournals.org/content/suppl/2021/04/06/molpharm.120.000071.DC1 1521-0111/99/5/319–327$35.00 https://doi.org/10.1124/molpharm.120.000071 MOLECULAR PHARMACOLOGY Mol Pharmacol 99:319–327, May 2021 Copyright ª 2021 The Author(s). This is an open access article distributed under the CC BY Attribution 4.0 International license. Inhibition of Bitter Taste from Oral Tenofovir Alafenamide s Erik Schwiebert,2 Yi Wang,1,2 Ranhui Xi, Katarzyna Choma, John Streiff, Linda J. Flammer, Natasha Rivers, Mehmet Hakan Ozdener, Robert F. Margolskee, Carol M. Christensen, Nancy E. Rawson, Peihua Jiang, and Paul A. S. Breslin Discovery Biomed, Birmingham, Alabama (E.S., J.S.); Monell Chemical Senses Center, Philadelphia, Pennsylvania (Y.W., R.X., K.C., L.J.F., N.R., M.H.O., R.F.M., C.M.C., N.E.R., P.J., P.A.S.B.); and Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey (P.A.S.B.) Received May 14, 2020; accepted March 1, 2021 Downloaded from ABSTRACT Children have difficulty swallowing capsules. Yet, when pre- 16 subjects showed reduction in perceived bitterness of TAF sented with liquid formulations, children often reject oral med- after pretreating (or “prerinsing”) with 6-methylflavone and ications due to their intense bitterness. Presently, effective mixing 6-methylflavone with TAF. Bitterness was completely strategies to identify methods, reagents, and tools to block and reliably blocked in two of these subjects. These data molpharm.aspetjournals.org bitterness remain elusive. For a specific bitter-tasting drug, demonstrate that a combined approach of human taste cell identification of the responsible bitter receptors and discovery culture–based screening, receptor-specific assays, and hu- of antagonists for those receptors can provide a method to man psychophysical testing can successfully discover mol- block perceived bitterness.
    [Show full text]
  • Genetic Diversity of Bitter Taste Receptor Gene Family in Sichuan Domestic and Tibetan Chicken Populations
    c Indian Academy of Sciences RESEARCH ARTICLE Genetic diversity of bitter taste receptor gene family in Sichuan domestic and Tibetan chicken populations YUAN SU, DIYAN LI, UMA GAUR, YAN WANG, NAN WU, BINLONG CHEN, ZHONGXIAN XU, HUADONG YIN, YAODONG HU and QING ZHU∗ Farm Animal Genetic Resources Exploration and Innovation Key Laboratory of Sichuan Province, Sichuan Agricultural University, Chengdu 611130, People’s Republic of China Abstract The sense of bitter taste plays a critical role in animals as it can help them to avoid intake of toxic and harmful substances. Previous research had revealed that chicken has only three bitter taste receptor genes (Tas2r1, Tas2r2 and Tas2r7). To better understand the genetic polymorphisms and importance of bitter taste receptor genes (Tas2rs) in chicken, here, we sequenced Tas2rs of 30 Sichuan domestic chickens and 30 Tibetan chickens. Thirteen single-nucleotide polymorphisms (SNPs) including three nonsynonymous mutations (m.359G>C, m.503C>A and m.583A>G) were detected in Tas2r1 (m. is the abbreviation for mutation); three SNPs were detected in Tas2r2, but none of them were missense mutation; eight SNPs were detected in Tas2r7 including six nonsynonymous substitutions (m.178G>A, m.421A>C, m.787C>T, m.832G>T, m.907A>Tand m.943G>A). Tajima’s D neutral test indicates that there is no population expansion in both populations, and the size of the population is relatively stable. All the three networks indicate that red jungle fowls share haplotypes with domestic chickens. In addition, we found that haplotypes H1 and HE1 were positively associated with high-altitude adaptation, whereas haplotypes H4 and HE4 showed a negative correlation with high-altitude adaptation in Tas2rs.
    [Show full text]
  • Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib
    Supplementary Online Content Chen G, McQuade JL, Panka DJ, et al. Clinical, molecular and immune analysis of dabrafenib-trametinib combination treatment for metastatic melanoma that progressed during BRAF inhibitor monotherapy: a phase 2 clinical trial. JAMA Oncology. Published online April 28, 2016. doi:10.1001/jamaoncol.2016.0509. eMethods. eReferences. eTable 1. Clinical efficacy eTable 2. Adverse events eTable 3. Correlation of baseline patient characteristics with treatment outcomes eTable 4. Patient responses and baseline IHC results eFigure 1. Kaplan-Meier analysis of overall survival eFigure 2. Correlation between IHC and RNAseq results eFigure 3. pPRAS40 expression and PFS eFigure 4. Baseline and treatment-induced changes in immune infiltrates eFigure 5. PD-L1 expression eTable 5. Nonsynonymous mutations detected by WES in baseline tumors This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 09/30/2021 eMethods Whole exome sequencing Whole exome capture libraries for both tumor and normal samples were constructed using 100ng genomic DNA input and following the protocol as described by Fisher et al.,3 with the following adapter modification: Illumina paired end adapters were replaced with palindromic forked adapters with unique 8 base index sequences embedded within the adapter. In-solution hybrid selection was performed using the Illumina Rapid Capture Exome enrichment kit with 38Mb target territory (29Mb baited). The targeted region includes 98.3% of the intervals in the Refseq exome database. Dual-indexed libraries were pooled into groups of up to 96 samples prior to hybridization.
    [Show full text]